Une lésion intra-utérine atypique : tumeur myofibroblastique inflammatoire (TMI)

Coffin, 2013, Inflammatory myofibroblastic tumor, 83 Lovly, 2014, Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions, Cancer Discov, 4, 889, 10.1158/2159-8290.CD-14-0377 Antonescu, 2015, Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement, Am J Surg Pathol, 39, 957, 10.1097/PAS.0000000000000404 Haimes, 2017, Uterine inflammatory myofibroblastic tumors frequently harbor ALK. Fusions with IGFBP5 and THBS1, Am J Surg Pathol, 41, 773, 10.1097/PAS.0000000000000801 Bennett, 2017, Inflammatory myofibroblastic tumor of the uterus : a clinicopathological, immunohistochemical, and molecular analysis of 13 cases highlighting their broad morphologic spectrum, Mod Pathol, 30, 1489, 10.1038/modpathol.2017.69 Subbiah., 2015, STUMP un“stumped”: anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion, J Hematol Oncol, 8, 66, 10.1186/s13045-015-0160-2 Butrynski, 2010, Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor, N Engl J Med, 363, 1727, 10.1056/NEJMoa1007056 Parra-Herran, 2015, Inflammatory myofibroblastic tumor of the uterus. Clinical and pathologic review of 10 cases including a subset with aggressive clinical course, Am J Surg Pathol, 39, 157, 10.1097/PAS.0000000000000330 Parra-Herran, 2016, Myxoid leiomyosarcoma of the uterus: a clinicopathologic analysis of 30 cases and review of the literature with reappraisal of its distinction from other uterine myxoid mesenchymal neoplasms, Am J Surg Pathol, 40, 285, 10.1097/PAS.0000000000000593 Schaefer., 2017, Abnormal p53 and p16 staining patterns distinguish uterine leiomyosarcoma from inflammatory myofibroblastic tumour, Histopathology, 70, 1138, 10.1111/his.13176